Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1)
1 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
2 Psychiatric Research Institute of Montefiore Einstein, Albert Einstein College of Medicine, Bronx, NY, USA.
3 Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, USA.
4 University of Southampton Faculty of Medicine, Southampton, United Kingdom.
5 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; South West London and St George's NHS Mental Health Trust, United Kingdom.
6 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; Centre for Psychedelic Research, Imperial College London, London, United Kingdom. Electronic address: luca.pellegrini@nhs.net.
7 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
8 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Cornwall Partnership NHS Foundation Trust, Cornwall, United Kingdom.